P21 No Adamantane

Compound Overview

Research Use Only. Not for Human Consumption.

P21 No Adamantane is supplied by Nexus as a 10mg lyophilized research compound in the Cognitive & Nootropic category. The supplied research record classifies it as a CNTF-derived neurotrophic peptide analog and describes it as an unmodified, no-adamantane P21-style peptide analog.

This product page is intentionally constrained by the available source data. The product name P21 No Adamantane does not, by itself, establish a unique public chemical structure. The source record specifically warns that the exact sequence, terminal cap state, molecular formula, molecular weight, and CAS number are not confirmed for final publication. Those fields are therefore not inferred from adamantane-modified P021 references or from adjacent P21-style materials.

• Product: P21 No Adamantane
• Available Research Size: 10mg
• SKU: P210
• Catalog Category: Cognitive & Nootropic
• Classification: CNTF-derived neurotrophic peptide analog
• Structural Description: Unmodified / no-adamantane P21-style peptide analog; supplier sequence must be confirmed before final chemistry publication
• Sequence Display: Commonly marketed near DGGLAG-type P21 analogs; exact uncapped sequence requires confirmation
• Physical Form: Lyophilized powder
• Use: For in-vitro research use only. Not for human consumption.

Research Background & Published Literature

The provided research background places P21 No Adamantane in the P021 / P21 analog family. It also distinguishes this Nexus-only SKU from adamantane-modified P021, which is described more consistently in public references than the no-adamantane analog. That distinction matters because removing the adamantane descriptor does not automatically produce one validated public structure.

For this reason, this description does not publish a CAS number, formula, molecular weight, purity value, cap state, or complete peptide sequence. The available data supports only a conservative research description: P21 No Adamantane is an unmodified / no-adamantane P21-style peptide analog supplied as lyophilized powder for in-vitro research workflows.

The supplied research record lists the following public reference sources:

These sources are included because they appear in the provided research data. They should not be treated as batch-level analytical documentation, and they do not replace supplier confirmation of sequence, cap state, HPLC profile, or mass-spectrometry identity for this specific no-adamantane SKU.

Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:

• Li et al. (2010) — FEBS Lett
• Bolognin et al. (2014) — Neurobiol Aging
• Kazim et al. (2014) — Neurobiol Dis

Storage, Handling & Stability Guidelines

The supplied storage guidance is to store lyophilized P21 No Adamantane at -20°C, desiccated, and protected from light. After reconstitution, the source record advises aliquoting the material and avoiding repeated freeze-thaw cycles.

• Store sealed lyophilized material at -20°C.
• Keep the vial desiccated during storage to limit moisture exposure.
• Protect the material from light during storage and handling.
• After reconstitution, aliquot material according to validated laboratory SOPs.
• Avoid repeated freeze-thaw cycles after reconstitution.
• Maintain internal traceability between the vial, SKU P210, receiving documentation, and any available analytical records.

The source data does not provide a validated reconstitution solvent, working concentration, post-reconstitution expiration interval, stability-study result, or temperature-excursion tolerance. Those values should be determined only from current supplier documentation, lot-specific analytical records, and the receiving laboratory's validated procedures.

Lab Verification

Nexus maintains research-compound verification information through the Lab Verified archive. For P21 No Adamantane, the supplied source data does not include exact COA values, purity values, batch numbers, HPLC retention data, or mass-spectrum values, so this description does not present a lot-specific COA panel.

In general terms, identity and quality review for peptide research materials should include HPLC purity assessment and Mass Spectrometry identity confirmation where current lot documentation is available. For this product specifically, analytical review is especially important because the source record states that the no-adamantane product name does not establish exact sequence, terminal caps, or molecular mass.

Before initiating an in-vitro workflow, review any current documentation available through /lab-verified and reconcile the product name, SKU, sequence information, cap state, and analytical identity against the received vial and internal inventory record.